Acumen pharmaceuticals to present studies on cost savings associated with use of ptau217 screening assay in phase 2 altitude-ad study and sabirnetug oligomer-selectivity at the alzheimer's association international conference (aaic®) 2025

Newton, mass., july 10, 2025 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (aΒos) for the treatment of alzheimer's disease (ad), will present new findings at the upcoming alzheimer's association international conference (aaic®) 2025 in toronto. the presentations include a cost savings analysis of the use of ptau217 as a screening tool in acumen's phase 2 altitude-ad trial of sabirnetug as well as a nonclinical study evaluating the relative selectivity of sabirnetug to targeting aΒos versus aΒ monomers. the conference will be held july 27-31, 2025, both in-person and online.
ABOS Ratings Summary
ABOS Quant Ranking